Glasgow L A, Richards J T, Kern E R
Am J Med. 1982 Jul 20;73(1A):132-7. doi: 10.1016/0002-9343(82)90078-x.
Murine cytomegalovirus (MCMV) is inhibited in vitro by 1 to 2 microM acyclovir. Therapy of a systemic MCMV infection in weanling mice with acyclovir was only minimally effective when drug was administered intraperitoneally, while oral administration by addition of acyclovir to the drinking water was highly efficacious in mice with disseminated MCMV. Effective therapy was characterized by reduction of virus titers in lung, liver, spleen, and kidney. In mice chronically infected with MCMV, treatment for 30 days with oral acyclovir eliminated or reduced virus titers in all target organs except the salivary gland. Therapeutic efficacy in this model infection using oral administration of acyclovir could be correlated with the achievement of acyclovir levels in the plasma of experimental animals two to 10 times greater than the mean inhibitory concentration for MCMV in vitro throughout treatment. The lack of efficacy observed when drug was administered intraperitoneally was associated with acyclovir levels exceeding 1 microM for one to three hours after each dose.
鼠巨细胞病毒（MCMV）在体外可被1至2微摩尔的阿昔洛韦抑制。用阿昔洛韦治疗断奶小鼠的全身性MCMV感染时，经腹腔给药效果甚微，而在饮用水中添加阿昔洛韦进行口服给药对播散性MCMV感染的小鼠则非常有效。有效治疗的特征是肺、肝、脾和肾中的病毒滴度降低。在慢性感染MCMV的小鼠中，口服阿昔洛韦治疗30天可消除或降低除唾液腺外所有靶器官中的病毒滴度。在该模型感染中，口服阿昔洛韦的治疗效果与实验动物血浆中阿昔洛韦水平在整个治疗过程中比体外MCMV的平均抑制浓度高两到十倍相关。腹腔给药时观察到的疗效不佳与每次给药后一至三小时阿昔洛韦水平超过1微摩尔有关。
